SAHPRA and the Medical Devices Unit: Regulator Mandate and Scope

1. Key takeaways

The statutory regulator for medical devices in South Africa is the South African Health Products Regulatory Authority (SAHPRA), whose internal Medical Devices Unit handles the issuance of Medical Device Establishment Licences and the registration of medical devices (covering both IVDs and non-IVDs), with the objective of ensuring that devices supplied in South Africa reach acceptable levels of safety, quality and performance. SAHPRA also houses the Radiation Control function, which means that radiation-emitting devices involve two separate licences. For external communication, licence applications, vigilance reports and registration enquiries each run through distinct channels, and companies should engage SAHPRA on separate tracks according to the matter at hand. Treating SAHPRA as a single inbox is a reliable recipe for delay: submissions land in the wrong queue, deadlines are measured against the wrong clock, and the Authority’s response times cannot be tracked coherently. A channel map, maintained as a living document, should be part of every South African market entry plan from the first day of preparation.

2. Legal basis

3. Expert insights

Insight one: SAHPRA’s mandate reaches far beyond the word devices. According to its official functional description, SAHPRA’s powers over medical devices include monitoring, evaluation, regulation, investigation, inspection, registration and control. This chain of verbs determines what companies will actually face: not only technical review, but also on-site inspection, sampling and testing, market surveillance and investigation. Any organisation that models SAHPRA as an authority that merely reviews paperwork will pay the price at the inspection stage, when document trails, site records and complaint handling are examined against the promises made in the licence application.

Insight two: the Medical Devices Unit and Radiation Control are two parallel functional lines. Radiation-emitting devices (such as X-ray equipment, MRI systems and certain ultrasound devices) require a Radiation Control licence in addition to an establishment licence. Since the radiation control function was merged into SAHPRA, both licences can be initiated through one submission, but they are still issued separately. Companies should schedule these two lines in parallel and never assume that a single submission equals a single certificate; approval timelines for the two licences differ, and delays in either can hold up commercial launch.

Insight three: licensing, vigilance and registration each have independent intake channels. Licence applications are submitted through the channels designated by SAHPRA; vigilance and adverse event reports go to the dedicated mailbox mdvigilance@sahpra.org.za using the Medical Device Adverse Event Reporting Form (GLF-MD-11A); registration-related enquiries and feasibility study matters are handled through dedicated mailboxes such as mdreg@sahpra.org.za. Misdirected submissions are the most common source of avoidable delay in South African practice, because correspondence sent to the wrong channel may sit unprocessed while formal deadlines continue to run.

Insight four: SAHPRA uses reliance as a resource allocation strategy. The official formulation states that the goal is the optimal use of available resources and expertise, avoidance of duplication, and the concentration of regulatory effort where it is most needed. This is not a slogan: the Medical Devices Reliance Guideline (SAHPGL-MD-22, dated 25 February 2026) turns it into concrete pathways that can be used in licensing, registration, clinical trials, ISO 13485 audits, and post-market and market surveillance. Understanding this explains why South Africa leans so heavily on FDA and CE evidence. Companies holding approvals from reference authorities should organise their evidence around reliance from the outset rather than as an afterthought.

Insight five: the guidelines leave room for requests for additional information. SAHPRA guidelines generally state that the Authority retains the right to request additional information to confirm the safety, quality and performance of a device, based on the knowledge available at the time of assessment. This means that a dossier matching the guideline checklist does not guarantee that no further information will be requested. Companies should build a correction window into their project schedules instead of assuming approval will follow mechanically once the listed items are complete.

4. Practical recommendations

1. Engage by matter and channel: maintain separate contact records for licensing, vigilance, registration and radiation control.
2. Run dual timelines for radiation-emitting devices: pursue the establishment licence and the Radiation Control licence in parallel.
3. Maintain a SAHPRA correspondence log: record the date, channel, counterpart unit and outcome of every communication.
4. Organise evidence around reliance: prioritise approval documents from reference authorities such as the FDA, CE notified bodies and the TGA.
5. Reserve a correction window: do not schedule projects on the assumption of first-pass approval.
6. Subscribe to SAHPRA medical device communications: policy milestones are announced through these communications.

5. Verification checklist

• □ Verify that the SAHPRA Medical Devices Unit is the competent unit for the company’s matters
• □ Verify that the establishment licence and the Radiation Control licence are tracked as separate lines
• □ Verify that the current version of the licence application form has been obtained (GLF-MD-06A series)
• □ Verify that the vigilance reporting channel and form are on record (GLF-MD-11A)
• □ Verify that a SAHPRA communication log is maintained (date, channel, matter, outcome)
• □ Verify that reference authority approval evidence has been organised according to the reliance approach
• □ Verify that a correction window is built into the project schedule
• □ Verify that SAHPRA medical device communications and guideline updates are subscribed

Regulatory information verified as of 29 October 2026. The instruments, guidelines and effective dates described in this article are limited to the content published by the official sources listed under the legal basis above as at that date; where official documents are updated, the latest published version prevails.

• South Africa local support: GRZAN assists manufacturers in the Chinese mainland and abroad with SAHPRA Medical Device Establishment Licence (MDEL) applications and product registration preparation, including Authorised Representative (AR) arrangements, ISO 13485 certification pathway planning and CAB selection, GMDN coding and classification decisions, technical documentation, and the setup of vigilance and adverse event reporting mechanisms.
• Service capabilities: product attribute determination and risk classification (Class A, B, C, D), establishment licence applications and renewals, reliance pathway arguments, technical documentation and essential principles conformity arguments, labelling and instructions for use localisation in English, and post-market vigilance and annual compliance submissions.
• Contact: info@grzanglobal.com; hito.lin@grzan.cn; website www.grzan.cn.